Evidence map›Paper›PMID 41614177›Full record

ArticleJACS Au2026

Aptamer-Mediated Covalent Dual Lysosome-Targeting Chimeras Enhance Targeted Degradation of Cell Surface Proteins.

Tao Peng, Min Su, Zuying Zhang, Ya Wang, Yingdi Zhu, Juan Li

Abstract read
In one paragraph

Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tao PengSchool of Chemistry and Materials, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
Min SuZhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P. R. China.
Zuying ZhangSchool of Chemistry and Materials, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.
Ya WangZhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P. R. China.
Yingdi ZhuZhejiang Cancer Hospital, Zhejiang Key Laboratory of Functional Nucleic Acids for Basic and Clinical Application, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, P. R. China.ORCID https://orcid.org/0000-0001-5584-3513
Juan LiSchool of Chemistry and Materials, University of Science and Technology of China, Hefei, Anhui 230026, P. R. China.ORCID https://orcid.org/0000-0001-7175-2320

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aptamer-based lysosome-targeting chimeras (Apt-LYTACs) have emerged as a promising strategy for the selective degradation of cell surface proteins by linking a target-specific aptamer to a lysosome-trafficking receptor ligand. However, their degradation efficiency is often limited by weak noncovalent interactions, heterogeneous receptor distribution, and the constraints of a 1:1 complex stoichiometry. To address these challenges, we developed aptamer-mediated covalent dual lysosome-targeting chimeras (Apt-cdLYTACs), which enable specific covalent anchoring to the protein of interest with spatiotemporal control by combining the specificity of aptamer recognition with proximity-induced photoreactive cross-linking. These chimeras incorporate two lysosomal receptor ligands to enhance the local avidity and promote multivalent complex formation. Compared to conventional noncovalent or single-ligand covalent Apt-LYTAC, Apt-cdLYTAC forms more stable degradation complexes, exhibits prolonged intracellular retention, and reduces efflux, thereby significantly improving degradation efficiency. Apt-cdLYTAC provides a modular, efficient, and user-friendly platform for the selective degradation of membrane proteins, with broad potential for applications in biochemical research and therapeutic development.

Indexed as

aptamercovalentdual lysosome-targeting ligandLYTACtargeted protein degradation

Identifiers

PMID41614177
PMCPMC12848693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.